| answer text |
<p>The National Institute for Health and Care Excellence (NICE) is the independent
body responsible for providing guidance on the prevention and treatment of ill health
and the promotion of good health and social care for the National Health Service.
NICE has provided recommendations on the use of tamoxifen in its clinical guideline
on ‘Early and locally advanced breast cancer: diagnosis and treatment’ which is currently
being updated. The guideline can be found at:</p><p><a href="https://www.nice.org.uk/guidance/cg80/chapter/1-Guidance#endocrine-therapy"
target="_blank">https://www.nice.org.uk/guidance/cg80/chapter/1-Guidance#endocrine-therapy</a></p><p>The
Breast Cancer Clinical Expert Group also issued guidance to Cancer Alliances for Provision
of Breast Cancer Services, in August 2017. This guidance includes best practice for
the provision of tamoxifen, and can be found at:</p><p><a href="http://www.yhscn.nhs.uk/media/PDFs/cancer/National%20Optimal%20Pways%202017/Clinical%20Advice%20for%20the%20Provision%20of%20Breast%20Cancer%20Services%20Aug%202017.pdf"
target="_blank">http://www.yhscn.nhs.uk/media/PDFs/cancer/National%20Optimal%20Pways%202017/Clinical%20Advice%20for%20the%20Provision%20of%20Breast%20Cancer%20Services%20Aug%202017.pdf</a></p>
|
|
